Clinical Trials Search
A Phase II Biomarker Trial of Avadomide (CC-122) in Combination with Nivolumab in Advanced Melanoma
This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune response).
Primary: To determine the response rate to combination CC-122 plus nivolumab in both anti-PD1 naïve and anti-PD1 refractory advanced melanoma. Secondary: (1) To assess the toxicity of this combination. (2) To determine the progression-free survival and overall survival with this combination. (3) Examine blood and tissue-based biomarkers that will further our understanding of the complex interplay between the metabolic needs/changes in the tumor and the immune microenvironment.
BMS-936558 (Nivolumab); CC-122 (); Nivolumab ()